Literature DB >> 15354618

Cyclosporine A and adverse effects on organs: histochemical studies.

Rita Rezzani1.   

Abstract

The discovery that cyclosporine A (CsA) was a powerful immunosuppressant had a significant impact on transplant medicine. Its molecular mechanism of action has been well defined in T cells and involved inhibition of critical signalling pathways that regulated T-cell activation. In fact, CsA inhibited calcineurin phosphatase activity and thereby activation of the transcription factor nuclear factor of activated T cells. Over 10 years, its use is limited by side effects, determining nephro- and hepatotoxicity, gingival hypertrophy, tremor and increased blood pressure. These negative effects have been identified through morphological alterations and/or clinical parameters, i.e. variation in glomerular filtration rate for nephrotoxicity. Nevertheless, CsA remains a therapeutic valuable agent and it is normally utilized into clinical practice even if different dose adjustments or discontinuations in a significant percentage of patients must be used. This review focuses on the following topics: mechanisms of action and drug metabolism, interactions with other drugs, clinical and morphological evaluation of toxic effects on target organs. In particular, the morphological evaluation of negative effects has been considered reporting light and ultrastructural studies on target organs both in normal and immunosuppressive conditions. Moreover, the histochemical and immunohistochemical variations in cellular metabolism and antigenic properties of cells present in the parenchyma of these organs are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15354618     DOI: 10.1016/j.proghi.2004.04.001

Source DB:  PubMed          Journal:  Prog Histochem Cytochem        ISSN: 0079-6336


  32 in total

1.  Nanoparticles made of multi-block copolymer of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups for oral delivery of cyclosporine A.

Authors:  D D Ankola; A Battisti; R Solaro; M N V Ravi Kumar
Journal:  J R Soc Interface       Date:  2010-05-26       Impact factor: 4.118

2.  Provinol prevents CsA-induced nephrotoxicity by reducing reactive oxygen species, iNOS, and NF-kB expression.

Authors:  Barbara Buffoli; Olga Pechánová; Stanislava Kojsová; Ramaroson Andriantsitohaina; Lorena Giugno; Rossella Bianchi; Rita Rezzani
Journal:  J Histochem Cytochem       Date:  2005-06-13       Impact factor: 2.479

Review 3.  Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson's disease.

Authors:  Zubin Master; Marcus McLeod; Ivar Mendez
Journal:  J Med Ethics       Date:  2007-03       Impact factor: 2.903

4.  Cyclosporine exacerbates ketamine toxicity in zebrafish: Mechanistic studies on drug-drug interaction.

Authors:  Bonnie L Robinson; Melanie Dumas; Syed F Ali; Merle G Paule; Qiang Gu; Jyotshna Kanungo
Journal:  J Appl Toxicol       Date:  2017-06-01       Impact factor: 3.446

5.  Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial.

Authors:  Anna Teresa Mazzeo; Gretchen M Brophy; Charlotte B Gilman; Oscar Luís Alves; Jaime R Robles; Ronald L Hayes; John T Povlishock; M Ross Bullock
Journal:  J Neurotrauma       Date:  2009-12       Impact factor: 5.269

6.  Domain architecture of the regulators of calcineurin (RCANs) and identification of a divergent RCAN in yeast.

Authors:  Sohum Mehta; Huiming Li; Patrick G Hogan; Kyle W Cunningham
Journal:  Mol Cell Biol       Date:  2009-03-09       Impact factor: 4.272

7.  Human structural proteome-wide characterization of Cyclosporine A targets.

Authors:  Gang Hu; Kui Wang; Jody Groenendyk; Khaled Barakat; Marcin J Mizianty; Jishou Ruan; Marek Michalak; Lukasz Kurgan
Journal:  Bioinformatics       Date:  2014-08-28       Impact factor: 6.937

Review 8.  NFAT proteins: emerging roles in cancer progression.

Authors:  Maria Mancini; Alex Toker
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

9.  Biopharmaceutical Evaluation of Novel Cyclosporine A Nano-matrix Particles for Inhalation.

Authors:  Hideyuki Sato; Hiroki Suzuki; Keisuke Yakushiji; Jennifer Wong; Yoshiki Seto; Robert K Prud'homme; Hak-Kim Chan; Satomi Onoue
Journal:  Pharm Res       Date:  2016-05-25       Impact factor: 4.200

10.  Chimerism-based experimental models for tolerance induction in vascularized composite allografts: Cleveland clinic research experience.

Authors:  Maria Siemionow; Aleksandra Klimczak
Journal:  Clin Dev Immunol       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.